These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6685518)

  • 1. [Concentration of cefadroxil in kidney tissue and serum after oral administration in patients with normal and impaired renal function].
    Degen J; Ringwelski L; Maier-Lenz H
    Arzneimittelforschung; 1983; 33(9):1339-42. PubMed ID: 6685518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of cefadroxil administered orally to rabbits with experimentally induced renal impairment.
    Mariño EL; Pajares M; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    Arzneimittelforschung; 1981; 31(9):1459-61. PubMed ID: 7197955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefadroxil kinetics in patients with impaired renal function.
    Cutler R
    J Int Med Res; 1980; 8(Suppl 1):17-20. PubMed ID: 7439499
    [No Abstract]   [Full Text] [Related]  

  • 4. Cimetidine pharmacokinetics after oral administration of cimetidine retard in normal and impaired renal function.
    Shaheen RA; Zazgornik J; Kuska J; Kokot F; Schneider J
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):480-6. PubMed ID: 2272709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of experimentally induced renal impairment on the pharmacokinetics of cefadroxil in rabbits.
    Mariño EL; Dominguez-Gil AA; Cepeda M; Otero MJ; Dominguez-Gil A
    Arzneimittelforschung; 1981; 31(3):478-81. PubMed ID: 7194673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Cytembena in chronic renal impairment.
    Schück O; Grafnetterová J; Sotorník I
    Neoplasma; 1976; 23(2):161-70. PubMed ID: 947088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice.
    Shen H; Ocheltree SM; Hu Y; Keep RF; Smith DE
    Drug Metab Dispos; 2007 Jul; 35(7):1209-16. PubMed ID: 17452417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function.
    Moellering RC; Krogstad DJ; Greenblatt DJ
    Rev Infect Dis; 1981; 3 suppl():S230-5. PubMed ID: 7342286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function.
    Hojs R; Bevc S; Ekart R; Gorenjak M; Puklavec L
    Nephrol Dial Transplant; 2006 Jul; 21(7):1855-62. PubMed ID: 16524933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on the pharmacokinetics of pipemidic acid in renal insufficiency (author's transl)].
    Brühl P; Köhler T; Gundlach G; Krasemann C
    Arzneimittelforschung; 1981; 31(10):1766-70. PubMed ID: 7198452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating type VI collagen and undulin, in patients with kidney diseases, after kidney transplantation and on hemodialysis.
    Marder K; Keller F; Schuppan D
    Clin Nephrol; 1995 Sep; 44(3):178-84. PubMed ID: 8556834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperhomocysteinemia in children on renal replacement therapy.
    Feinstein S; Sela BA; Drukker A; Becker-Cohen R; Raveh D; Gavendo S; Frishberg Y
    Pediatr Nephrol; 2002 Jul; 17(7):515-9. PubMed ID: 12172765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.
    Guay DR; Matzke GR; Bockbrader HN; Dancik J
    Clin Pharm; 1983; 2(2):157-62. PubMed ID: 6883944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of benoxaprofen in subjects with normal and impaired renal function, prediction of multiple-dose kinetics.
    Brogard JM; Comte F; Madon M; Spach MO
    Eur J Rheumatol Inflamm; 1982; 5(2):113-23. PubMed ID: 7084275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Yoshimoto M; Nishidai H; Nakanishi Y; Kashi Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1037-48. PubMed ID: 6721512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefapirin in patients with normal and impaired renal functions.
    Bergan T; Orjavik O; Brodwall EK
    Arzneimittelforschung; 1981; 31(10):1773-6. PubMed ID: 7198453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses.
    Barbhaiya RH
    Biopharm Drug Dispos; 1996 May; 17(4):319-30. PubMed ID: 8743403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.